<DOC>
	<DOCNO>NCT00814320</DOCNO>
	<brief_summary>The purpose study develop subcutaneous treatment option participant Primary Immunodeficiency Diseases ( PID ) allow administration Immune Globulin Intravenous ( Human ) , 10 % frequency IV administration .</brief_summary>
	<brief_title>Gammagard Liquid rHuPH20 PID</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Participant 2 year old time screen Written informed consent obtain either participant participant 's legally acceptable representative prior studyrelated procedure study product administration Participant diagnose PID disorder require antibody replacement define WHO criterion Participant complete complete Baxter Clinical Study Protocol No . 160601 receive regular IGIVtreatment mean interval 21 ± 3 day 28 ± 3 day , SC mean interval 5 16 day , period least 3 month prior enrollment minimum dose 300 mg/kg BW/4 week Participant serum trough level IgG &gt; 4.5 g/L last documented determination If female childbearing potential , participant present negative urine pregnancy test agree employ adequate birth control measure duration study Participant willing able comply requirement protocol Participant know history positive enrollment screen one following : Hepatitis B surface antigen ( HbsAg ) , polymerase chain reaction ( PCR ) Hepatitis C Virus ( HCV ) , PCR Human immunodeficiency virus ( HIV ) Type 1/2 Participant level alanine aminotransferase ( ALT ) aspartate amino transferase ( AST ) &gt; 2.5 time upper limit normal test laboratory Participant persistent severe neutropenia ( define absolute neutrophil count [ ANC ] &lt; = 500/mm3 ) Participant creatinine clearance ( CLcr ) value , calculate accord formula , &lt; 60 % normal age gender male : CLcr = [ ( 140 Age ( year ) ) * ( body weight ( kg ) ) ] / [ 72 * ( serum creatinine ( mg/dL ) ) ] female : CLcr = [ ( 140 Age ( year ) ) * ( body weight ( kg ) ) * 0.85 ] / [ 72 * ( serum creatinine ( mg/dL ) ) ] Participant diagnose , malignancy ( adequately treat basal cell squamous cell carcinoma skin carcinoma situ cervix ) within last 12 month prior enrollment ; participant treat immunosuppressive chemotherapeutic agent period exclude Participant history thrombotic episode ( include deep vein thrombosis , myocardial infarction , cerebrovascular accident , pulmonary embolism ) within last 12 month Participant abnormal protein loss ( protein lose enteropathy , nephrotic syndrome ) Participant anemia would preclude phlebotomy laboratory study Participant receive blood blood product IGIV , SC immunoglobulin , immune serum globulin ( ISG ) preparation , albumin within 6 month prior enrollment Participant ongoing history hypersensitivity persistent reaction ( urticaria , breathe difficulty , severe hypotension , anaphylaxis ) follow IGIV , SC immunoglobulin , and/or ISG infusion Participant immunoglobulin A ( IgA ) deficiency know anti IgA antibody Participant preventative ( prophylactic ) antibiotic stop antibiotic time enrollment Participant active infection start antibiotic therapy treatment infection within 7 day prior screen Participant bleed disorder anticoagulation therapy result platelet count le 20,000/μL International Normalized Ration ( INR ) &gt; 2X control , , opinion investigator would significant risk increase bleed bruise result SC therapy Participant total protein &gt; 9 g/dL participant myeloma , macroglobulinemia ( IgM ) paraproteinemia Participant know allergy hyaluronidase If female , participant pregnant lactating time study enrollment Participant participate another clinical study involve investigational product ( IP ) device within 30 day prior study enrollment schedule participate another clinical study involve IP device course study ; exception : Baxter Study No . 160601 Severe dermatitis would preclude adequate site safe product administration</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>